Award for Bilobil in Poland

The first place in the national competition "Consumer's Laurel 2007" in the category "Drugs for memory improvement" has been won by Krka's Bilobil. As in the last year, also this year Bilobil won the first place in its category.

The award was based on voting by the Polish people. Bilobil turned out to be the most popular drug for memory improvement in Poland. This year Bilobil was also appreciated by pharmacists who awarded it The Product of the Year 2007 within the products for memory improvement. So it appears that Bilobil is the most highly evaluated drug in its group by patients and specialists.

Bilobil was frequently selected by the Polish pharmacists and patients who in the last year awarded it a gold "Consumer's Laurel".

Bilobil was also twice awarded a statuette of Golden Otis.

Bilobil is a drug that contains natural Ginkgo biloba leaf substances which improve the metabolism in brain cells and the supply of oxygen to the brain. The active substances of the extract improve memory and concentration, and are beneficial for life energy. The clinical examination* which was carried out in Otolaryngology Clinic Collegium Medicum in Bydgoszcz proved that the drug improves brain functions, such as memory and the ability to concentrate. Bilobil also efficiently prevents dizziness and tingling in the ears. In 2004 the producer enriched the Bilobil brand in Poland by a new product. Bilobil forte contains a double dose of Ginkgo biloba extracts (80 mg) and is intended for the active part of the population enabling a longer and a more intensive mental effort.

About Krka
Krka is one of the top generic pharmaceutical companies in Europe. For further information, please visit www.krka.si.

Most Popular Now

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

MedImmune and Sanofi Pasteur form alliance to deve…

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop a...

Read more

FDA approves once-daily Qtern (dapagliflozin and s…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of typ...

Read more

Cooking at home tonight? It's likely cheaper and h…

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results sho...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]